

1  
2 The Causal Effects of Blood Iron and Copper on Lipid Metabolism  
3 Disease: Evidence from Phenome-wide Mendelian Randomization  
4 Study

5  
6 Jingqi Zhou<sup>1,2</sup>, Chang Liu<sup>1,3</sup>, Michael Francis<sup>4</sup>, Yitang Sun<sup>1</sup>, Moon-Suhn Ryu<sup>5</sup>, Arthur Grider<sup>6</sup>,  
7 Kaixiong Ye<sup>1,4\*</sup>

- 8  
9 1. Department of Genetics, University of Georgia, Athens, GA, USA  
10 2. School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R.  
11 China  
12 3. College of Life Sciences, Wuhan University, Wuhan, P. R. China  
13 4. Institute of Bioinformatics, University of Georgia, Athens, GA, USA  
14 5. Department of Food Science and Nutrition, University of Minnesota, St. Paul, MN, USA  
15 6. Department of Foods and Nutrition, University of Georgia, Athens, GA, USA

16  
17 \* Correspondence should be addressed to KY ([kaixiong.ye@uga.edu](mailto:kaixiong.ye@uga.edu))

18

19

## 20 **Abstract**

21 **Background** Blood levels of iron and copper, even within their normal ranges, have been  
22 associated with a wide range of clinical outcomes. Available epidemiological evidence on blood  
23 iron and copper association with potential clinical effects, such as lipid metabolism disorder, is  
24 inconsistent and scarce. This study aims to examine and disentangle the causal clinical effects of  
25 iron and copper.

26 **Methods** Genetic instruments for the blood level of iron and copper were curated from existing  
27 genome-wide association studies. Candidate clinical outcomes were identified based on a  
28 phenome-wide association study (PheWAS) between these genetic instruments and multiple  
29 phenotypes in 310,999 unrelated individuals of European ancestry from the UK Biobank. All  
30 signals passing stringent correction for multiple testing were followed by Mendelian  
31 randomization (MR) analyses, with replication in independent data sources where possible.

32 **Results** Genetically predicted higher blood levels of iron and copper are both associated with  
33 lower risks of iron deficiency anemia (OR = 0.75, 95% CI:0.67-0.85,  $p = 1.90 \times 10^{-06}$  for iron; OR  
34 = 0.88, 95% CI: 0.78-0.98,  $p = 0.03$  for cooper), lipid metabolism disorders and its two  
35 subcategories, hyperlipidemia (OR = 0.90, 95% CI:0.85-0.96,  $p = 6.44 \times 10^{-04}$  for iron; OR = 0.92,  
36 95% CI:0.87-0.98,  $p = 5.51 \times 10^{-03}$  for cooper) and hypercholesterolemia (OR = 0.90, 95%  
37 CI:0.84-0.95,  $p = 5.34 \times 10^{-04}$  for iron; OR = 0.93, 95% CI:0.89–0.99,  $p = 0.02$  for cooper).

38 Consistently, they are also associated with lower blood levels of total cholesterol and low-density  
39 lipoprotein cholesterol. Multiple sensitivity tests were applied to assess the pleiotropy and  
40 stability of the estimation, and consistent evidence across different approaches was obtained.  
41 Additionally, unique clinical effects of each blood mineral were also pinpointed, and sex-

42 stratified MR analysis further revealed the clinical implication of iron and copper exhibits some  
43 degree of sex differences.

44 **Conclusions** Our comparative PheWAS-MR study of iron and copper comprehensively  
45 characterized their shared and unique clinical effects, highlighting their novel causal roles in  
46 hyperlipidemia and hypercholesterolemia. Given the modifiable and variable nature of blood  
47 mineral status, these findings warrant further investigation.

48

49 **Keywords:** iron, copper, phenome-wide association study, Mendelian randomization, lipid  
50 metabolism disorder

51

## 52 **Introduction**

53 Iron (Fe) and copper (Cu) are two essential mineral nutrients for human health through its vital  
54 role in enzymatic reactions and cellular energy metabolism <sup>1, 2</sup>. Physiological processes that  
55 maintain these minerals homeostasis are overwhelmed by dietary loss, inappropriate iron  
56 absorption, inflammation, infection, liver disease, and disordered erythropoiesis. Disturbance to  
57 the systemic iron or copper homeostasis, including deficiency, excess, and even fluctuations in  
58 the normal ranges, could have clinical implications<sup>3</sup>. Iron deficiency, the most widespread  
59 micronutrient deficiency worldwide, is well-established to cause anemia, while iron overload can  
60 lead to chronic liver disease, cirrhosis, and hepatocellular carcinoma <sup>4, 5</sup>. Copper deficiency is  
61 responsible for the lethal Menkes syndrome, featured by developmental delay and intellectual  
62 disability, while copper overload results in Wilson's disease, characterized by hepatic cirrhosis  
63 and neurological deficits <sup>6</sup>. Furthermore, copper is essential for iron absorption, and copper  
64 deficiency impairs iron metabolism. The multiple interactions of copper and iron involving both  
65 the positive and negative aspects by which associated with various of disease <sup>7</sup>. For instance,  
66 epidemiological studies have reported elevated blood levels of iron and copper are associated  
67 with a higher risk of type 2 diabetes anemia and osteoarthritis (OA) <sup>8,9</sup>. Higher iron and copper  
68 have been associated with a reduced risk of hyperlipidemia and an improved blood lipid profile  
69 <sup>10, 11</sup>. However, conflicting associative patterns were also reported <sup>12</sup>. Given the crucial role of  
70 minerals, studying the health risks of iron and copper has important clinical guiding significance.  
71 Due to the limited data available and the fact that most studies were observational, it is uncertain  
72 whether the associations are causal and not biased by reverse causality or residual confounding.  
73 Moreover, the causality of iron and copper effect on overall health has not been clearly  
74 established.

75 Mendelian randomization (MR), a complementary approach to epidemiological observations,  
76 utilizes genetic variants as instrumental variables to approximate the lifetime status of an  
77 exposure (e.g., the blood level of a mineral) and evaluates its causal effect on a clinical outcome.  
78 The random allocation of alleles at conception and the natural direction of causality from genetic  
79 variants to phenotypes protect MR estimates from confounding and reverse causality<sup>13, 14</sup>. MR  
80 studies have been performed to evaluate the causality of specific mineral-outcome pairs, such as  
81 iron on stroke, coronary artery disease (CAD), Parkinson's disease, gout, and inflammatory  
82 bowel disease<sup>15, 16</sup>; copper on ischemic heart disease<sup>17</sup>. Compared to these hypothesis-driven  
83 MR studies with an obvious bias towards cardiovascular diseases, phenome-wide association  
84 study coupled with MR (PheWAS-MR) enables an unbiased and hypothesis-free scan through a  
85 wide range of phenotypes (i.e., phenome) and prioritized candidate clinical outcomes for MR  
86 causal inferences. Most importantly, few existing studies simultaneously examine multiple blood  
87 minerals at a phenome-wide scale to disentangle their confounded clinical effects<sup>18</sup>.

88 In this study, we systematically evaluated and compared the causal clinical effects of iron  
89 and copper. Genetic instruments for the blood level of iron and copper were curated from  
90 existing genome-wide association studies (GWAS) with the largest sample sizes. Candidate  
91 clinical outcomes were identified based on a phenome-wide association study between these  
92 genetic instruments and multiple disease outcomes from the UK Biobank. All signals passing  
93 stringent correction for multiple testing were followed by Mendelian randomization (MR)  
94 analyses, with replication in independent data sources where possible. Additionally, we  
95 examined the causal association between iron or copper levels and a subset of lipid profiles,  
96 which are essential biomarkers for lipid metabolism disease, in the secondary analysis with an  
97 independent dataset.

98 **Methods**

99

100 The guideline of Strengthening the Reporting of Observational Studies in Epidemiology  
101 (STROBE) (S1 Checklist) was followed in this study report. The UK Biobank project was  
102 approved by the North West Multi-Centre Research Ethics Committee and appropriate informed  
103 consent was obtained from participants. Data used in the project was accessed through an  
104 approved application to UK Biobank. Only a subset of unrelated White British individuals with  
105 high-quality genotype data (N = 310,999) were included in this study in order to minimize the  
106 complication of population structure. The study design of PheWAS-MR, replication, and  
107 sensitivity analysis was prespecified. A schematic of the overall study design is shown in Fig 1.

108 **Genetic instruments for blood iron and copper**

109 Genetic instrumental variables for the blood levels of iron and copper were selected from  
110 previous GWAS (Table 1). Based on a meta-analysis of 48,972 subjects of European descent  
111 performed by the Genetics of Iron Status consortium<sup>19</sup>, three single nucleotide polymorphisms  
112 (SNPs) were selected as genetic instruments for systemic iron status. All three of them are  
113 consistently associated with four iron status biomarkers, including serum iron, ferritin, transferrin,  
114 and transferrin saturation. Their effects on serum iron were used in MR analysis. They are very  
115 strong genetic instruments, with F-statistics ranging from 445 to 796 and collectively explaining  
116 approximately 3.8% of the variation in serum iron. They have been previously used in MR  
117 analysis of iron status<sup>20</sup>. Genetic variants associated with erythrocyte copper levels were  
118 identified in an Australian cohort (N = 2603)<sup>21</sup>. Two SNPs were selected for erythrocyte copper,  
119 which accounted for 4.60% of the phenotypic variance. For each blood mineral, a weighted  
120 polygenic risk score (GRS) was constructed for each UK Biobank participant by summing over  
121 selected SNPs weighted by their effect sizes.

## 122 **Study population**

123 The UK Biobank is a population-based prospective cohort established to study genetic and  
124 environmental determinants of human diseases. More than 500,000 individuals aged 40-69 years  
125 were recruited between 2006 and 2010, all of whom gave written consent and underwent  
126 baseline measurements. Participants donated blood samples for genotyping and biomarker  
127 analysis. Moreover, UK Biobank participants consented access to their electronic health records.  
128 Only participants fulfilling the following criteria were included in our analysis: genetic ancestry  
129 of Caucasian, included in genetic principal component analysis, not outliers for heterogeneity  
130 and missing genotype rate, no sex chromosome aneuploidy, no high degree of genetic kinship  
131 (i.e., ten or more third-degree relatives identified), and self-reported sex matching genetic sex.  
132 Additionally, for remaining pairs of relatives (kinship coefficient  $> 0.0884$ ), a minimum number  
133 of participants were removed so that all remaining participants are unrelated. Analysis was  
134 restricted to participants of Caucasian descent in order to maintain consistency with the  
135 European samples used to obtain genetic instruments for blood mineral status. A total of 310,999  
136 unrelated individuals were included in our final analysis.

137

## 138 **Phenome wide association study**

139 Three phenotypic datasets in the UK Biobank, including inpatient hospital records, cancer  
140 registry, and death registry, were included in this analysis. First, we used the International  
141 Classification of Diseases (ICD) versions 9 and 10 to identify cases in the hospital episode  
142 statistics, including both incident and prevalent cases, but not self-reported diagnoses. As ICD-9  
143 / ICD-10 codes are not organized as independent phenotypes, we mapped them to the phecode  
144 system of distinct diseases or traits<sup>22</sup>. The mapping process also automatically excludes patients

145 with similar or potentially overlapping diseases from the corresponding control group. The  
146 online phecode map is accessible via the link [https://phewascatalog.org/phecodes\\_icd10](https://phewascatalog.org/phecodes_icd10). We  
147 restricted analysis to phecodes with sufficient numbers of cases to ensure more than 80%  
148 statistical power in subsequent MR analyses. The number of cases and controls in analyses of  
149 phenotypes for each blood mineral is shown in S1 Table.

150

151 For each mineral, case-control groups were generated for each phecode, and logistic regression  
152 was performed, separately, for each instrument SNP, adjusting for age, sex, genotyping array,  
153 assessment center, and the first 10 genetic principal components. Moreover, we explored the  
154 association between the weighted GRS of each blood mineral and the corresponding phecodes  
155 with logistic regression. Given that phenotypes investigated are not totally independent even in  
156 the phecode system, we applied the false discovery rate (FDR) method with a cutoff of 0.05 to  
157 correct for multiple testing.

158

### 159 **MR analyses**

160 To assess whether blood mineral levels have causal effects on the candidate clinical outcomes  
161 identified by the PheWAS, we further conducted two-sample MR analyses, where the  
162 instrument-mineral and instrument-outcome associations were estimated in two different samples.  
163 In this study, the instrument-mineral effect was estimated in previous GWAS, while the  
164 instrument-outcome effect was estimated in the above-mentioned PheWAS. To estimate the  
165 causal effect of each mineral on a phenotype, for each genetic instrument, we calculated the ratio  
166 of its effect on the phenotype to its effect on the blood mineral. An overall effect estimate across  
167 multiple genetic instruments was achieved with three methods, the inverse variance-weighted

168 (IVW) method, weighted median (WM) method, and MR-Egger<sup>23,24</sup>. Effect estimates, measured  
169 as OR of the outcome, were normalized to 1 standard deviation (SD) increment in each blood  
170 mineral. Additionally, sex-stratified IVW MR estimates were obtained with sex-specific  
171 instrument-outcome effects from genetically males and females, respectively. Mineral-outcome  
172 pairs exhibiting evidence of horizontal pleiotropy were excluded in this stratified analysis.

173 To validate some mineral-outcome relationships that we discovered based on UK Biobank, we  
174 performed replication analysis based on different cohorts, which were accessed through the MR-  
175 Base<sup>25</sup>. Specifically, for the four blood lipids, including total cholesterol (TC), high-density  
176 lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), and triglyceride, we  
177 extracted the instrument-outcome summary statistics from a previous GWAS by the Global  
178 Lipids Genetics Consortium (GLGC)<sup>26</sup>.

179  
180 To further evaluate if the effects of two minerals on a shared clinical outcome are independent of  
181 each other, we adopted a multivariable MR framework<sup>27</sup>, in which the effects of multiple  
182 related risk factors can be estimated simultaneously. For instance, to test if the effects of iron and  
183 copper on a shared clinical outcome (e.g., hyperlipidemia) are independent, we included all the  
184 genetic instruments for iron and copper in the analysis. The effect sizes of instrument SNPs on  
185 serum iron and erythrocyte copper were extracted from previous GWAS<sup>19,21</sup>, while their effects  
186 on the shared clinical outcome were calculated in our curated UK Biobank dataset. We modelled  
187 the SNP effects on the shared outcome ( $\beta_{\text{shared}}$ ) against the SNP effects on iron ( $\beta_{\text{Fe}}$ ), adjusted for  
188 the effects on copper ( $\beta_{\text{Cu}}$ ), using a weighted linear regression model ( $\beta_{\text{shared}} \sim \beta_{\text{Fe}} + \beta_{\text{Cu}}$ ), where  
189 the weights were defined by inverse standard errors of  $\beta_{\text{shared}}$ .

## 190 **Sensitivity analyses**

191 Several sensitivity analyses were performed to detect and correct for the presence of pleiotropy  
192 in the causal estimates. We began with the fixed-effect IVW MR approach, and calculated  
193 Cochran's Q statistic for heterogeneity, with which a p-value  $\leq 0.05$  indicates the presence of  
194 pleiotropy across genetic instruments. Heterogeneity across SNP-outcome associations will lead  
195 to bias in the fixed-effect IVW estimate. If substantial heterogeneity exists, we proceeded to a  
196 random-effect IVW approach, which allows instruments to exhibit balanced horizontal  
197 pleiotropy.

198

199 Because the IVW estimate is essentially a weighted average of the Wald ratios obtained from  
200 each SNP, if any of the SNPs exhibit horizontal pleiotropy, then the causal effect estimate is  
201 liable to be biased. We further performed WM MR<sup>24</sup> and MR-Egger analyses<sup>28</sup>. The WM  
202 analysis calculates the median of an empirical distribution of MR association estimates weighted  
203 by their precisions. It provides consistent estimates when more than half of the instruments are  
204 valid<sup>24</sup>. The MR-Egger method provides an intercept test, with a non-zero intercept indicating  
205 the presence of unbalanced horizontal pleiotropy. It also provides an unbiased estimate of the  
206 causal effect, taking into account pleiotropy. When there was no heterogeneity across  
207 instruments, a fixed-effect model was used to estimate the causal effect. Otherwise a random-  
208 effect model was used<sup>28</sup>.

209

210 Besides the above-mentioned sensitivity analyses that leverage information from multiple  
211 genetic instruments for one blood mineral, for each individual genetic instrument, we also

212 evaluated their pleiotropic effects by searching the GWAS catalog and PhenoScanner V2<sup>29</sup>, to  
213 identify any secondary phenotypes associated ( $p < 5 \times 10^{-8}$ ) with them or their proxies ( $r^2 > 0.8$ ).  
214 All analyses were conducted using the MendelianRandomisation<sup>30</sup> and TwoSampleMR<sup>25</sup>  
215 packages, and the R programming language.  
216

## 217 **Results**

218 After quality controls on the full UK Biobank dataset, a subset of 310,999 unrelated individuals  
219 of European descent were included in the PheWAS analysis. Main demographic characteristics  
220 of the study population and basic statistics of all genetic instruments are summarized in S2 Table.  
221 All instrument SNPs satisfied the Hardy-Weinberg equilibrium test ( $p > 0.05$ ). The association  
222 between the weighted GRS of each blood mineral and common confounding factors (i.e., age,  
223 sex, genotyping array, assessment center, and the genetic principal components) are presented in  
224 S3 Table. All these factors were controlled for in the PheWAS analysis.

225  
226 PheWAS analysis was limited to phenotypes (i.e., phecodes) that had enough cases to ensure  
227 more than 80% statistical power in the subsequent MR analyses. Among them, 12 clinical  
228 outcomes, representing 6 disease categories, reached statistical significance at the 5% FDR  
229 threshold. Next, we performed MR analyses to examine the possible causal links between each  
230 of the significant outcomes identified in PheWAS. Mineral-outcome pairs exhibit consistent MR  
231 evidence for causal effects, without suggestions of heterogeneity and horizontal pleiotropy across  
232 genetic instruments based on Cochran's Q statistic and MR-Egger's intercept test were provided  
233 in test (S4 Tables).

234

### 235 **Shared and unique causal clinical effects of blood iron and copper**

236 Iron and copper share some of causally associated clinical outcomes, including iron deficiency  
237 anemia, disorders of lipid metabolism, hypercholesterolemia, and hyperlipidemia (Fig 2). IVW  
238 MR analyses provided significant evidence for causal effects of both higher blood iron and  
239 copper on reduced risks of iron deficiency anemia (OR per SD increase in serum iron = 0.75, 95%

240 CI: 0.67-0.85,  $p = 1.81 \times 10^{-6}$ ; OR per SD increase in erythrocyte copper = 0.88, 95% CI: 0.79-  
241 0.99,  $p = 0.032$ ) and disorders of lipid metabolism (OR per SD increase in serum iron = 0.90,  
242 95% CI: 0.85-0.96,  $p = 6.61 \times 10^{-4}$ ; OR per SD increase in erythrocyte copper = 0.92, 95% CI:  
243 0.87-0.98,  $p = 4.94 \times 10^{-3}$ ; ), and its two subtypes, hyperlipidemia (OR = 0.90, CI: 0.85-0.96,  $p =$   
244  $6.44 \times 10^{-4}$ ; OR = 0.92, CI: 0.87-0.98,  $p = 5.51 \times 10^{-3}$ ) and hypercholesterolemia (OR = 0.90, CI:  
245 0.84-0.95,  $p = 5.34 \times 10^{-4}$ ; OR = 0.93, CI: 0.88-0.99,  $p = 0.022$ ). Specifically, unique causal  
246 clinical effects were identified for iron and copper. Per SD increase in serum iron is associated  
247 with enhanced risk of varicose veins (OR = 1.28, CI: 1.15-1.42,  $p = 4.34 \times 10^{-6}$ ) and acquired foot  
248 deformities (OR = 1.21, CI: 1.09-1.35,  $p = 4.95 \times 10^{-4}$ ), but with reduced risk of other anemia (OR  
249 = 0.72; CI: 0.65-0.79;  $p = 1.12 \times 10^{-11}$ ). Per SD increment in erythrocyte copper is associated with  
250 increased risk of osteoarthritis (OA) (OR = 1.07, CI: 1.02-1.13,  $p = 0.010$ ).

251

### 252 **Causality of both Iron and Cooper on Lipid Metabolism Trait**

253 We performed further investigation into the shared clinical effects of serum iron and erythrocyte  
254 copper on lipid metabolism disorders, by first evaluating if they are independent of each other  
255 and then by examining their causal effects on blood biomarkers of lipid metabolism, including  
256 TC, HDL, LDL, and triglyceride. First, we adopted a multivariable MR framework to estimate  
257 the direct effects of serum iron and erythrocyte copper on their shared clinical outcomes, by  
258 conditioning on the effects of the other mineral. We found that the causal effects of iron and  
259 copper are independent of each other and do not show much differences compared to those of  
260 univariate MR (S5 Table). Based on the shared but independent effects of iron and copper on lipid  
261 metabolism disorders, we further hypothesized that their genetically predicted levels are  
262 associated with blood biomarkers of lipid metabolism. We tested this hypothesis with the UK

263 Biobank data with exclusion of participants under statin medication, and then in an independent  
264 replication cohort from the Global Lipids Genetics Consortium (GLGC) accessed through the  
265 MR-base database (Table 2). In both cohorts, genetically predicted higher levels of serum iron is  
266 associated with decreased levels of LDL (WM OR = 0.91, CI: 0.89-0.94,  $p = 5.27 \times 10^{-11}$  in  
267 UKBB) and TC (WM OR = 0.91, CI: 0.88-0.94,  $p = 8.99 \times 10^{-8}$  in UKBB), but elevated levels of  
268 triglycerides (WM OR = 1.05, CI: 1.02-1.07,  $p = 4.2 \times 10^{-5}$  in UKBB). No significant effects were  
269 found for HDL. For erythrocyte copper, while no significant effects were found in UK Biobank,  
270 analysis in the GCLC cohort showed that per SD increase in copper is associated with reduced  
271 levels of LDL (OR = 0.95, CI: 0.92-0.99,  $p = 0.011$  in GCLC) and TC (OR = 0.96, CI: 0.92-0.99,  
272  $p = 0.02$  in GCLC). Overall, we found evidence for the shared effects of iron and copper on  
273 reducing blood levels of LDL and TC.

274

### 275 **Interpretation of potential pleiotropy in PheWAS-MR results**

276 To detect and correct for any possible pleiotropic effect of multiple instruments, we then  
277 conducted the different sets of sensitivity analysis. All causal clinical effects of iron and copper  
278 presented above in combined analysis, except LDL and TC, do not have evidence for  
279 heterogeneity or horizontal pleiotropy across genetic instruments, as indicated by Cochran's Q  
280 statistic and MR-Egger's intercept test (S4 Tables). For some relationships, causal estimates  
281 from another methods, WM MR and MR-Egger, are broadly consistent with those from IVW  
282 MR, although with wider confidence intervals as expected from their lower statistical powers<sup>31</sup>.  
283 For instance, the causal estimates of serum iron on disorders of lipid metabolism were  
284 consistent in the IVW MR (OR = 0.90, CI: 0.85-0.96,  $p = 6.61 \times 10^{-4}$ ) and WM MR (OR= 0.91,

285 95% CI:0.85-0.97,  $p = 6.25 \times 10^{-3}$ ), and there was no evidence of pleiotropy ( $p \geq 0.05$  for all  
286 related tests).

287

288 Besides sensitivity analyses that leverage information from multiple genetic instruments for one  
289 blood mineral, for each individual instrument SNP, we also evaluated their pleiotropic effects by  
290 searching the GWAS catalog and PhenoScanner V2<sup>29</sup>. The HFE rs1800562 variant is associated  
291 with low-density lipoprotein cholesterol<sup>26</sup>, and this SNP were identified as pleiotropic with  
292 potential confounders. Similar magnitudes of associations were observed when these variants  
293 were excluded from the MR analyses. We additionally performed a sensitivity analysis of sex-  
294 stratified IVW MR to identify sex-specific causal clinical effects of these minerals. We identified  
295 mineral-outcome pairs exhibiting sex-specific causal relationships (Fig 3, Supplementary Tables  
296 6). That is, their MR estimates are significant only in one sex group, but not in the other or the  
297 sex-combined sample. Iron is associated with higher risks of myeloproliferative diseases (OR  
298 =2.20, CI: 1.37-3.53,  $p = 1.14 \times 10^{-3}$ ) in females and chronic liver disease (OR =1.47, CI: 1.07-  
299 2.03,  $p = 0.017$ ) in males. Specifically, copper increases the risk of diabetes mellitus (OR = 1.20,  
300 CI: 1.02-1.40,  $p = 0.027$ ) and its subcategory, T2D (OR = 1.19, CI: 1.00-1.40,  $p = 0.044$ ) in  
301 female. But serum iron and copper have no sex-specific effects on lipid metabolism disease.

302

303

## 304 **Discussion**

305 Our study adopted a phenome-wide approach to systematically evaluate and compare the clinical  
306 effects of blood iron and copper minerals. This is the first PheWAS-MR study for copper, and  
307 the first to perform systematic comparison across iron and copper. Our findings highlighted  
308 shared clinical effects, specifically the protective effects of iron and copper on lipid metabolism  
309 disorders and iron deficiency anemia. Some causal mineral-outcome relationships identified in  
310 this study have been well known and supported by existing mechanistic studies, while others are  
311 novel, awaiting further confirmation and future mechanistic exploration.

312 Most notably, we found that genetically predicted higher blood levels of iron and copper are  
313 both protective against lipid metabolism disorders and its two subcategories, hyperlipidemia and  
314 hypercholesterolemia. Consistently, they are also associated with lower blood TC and LDL. This  
315 is the first MR study to establish the causal protective effect of copper on lipid metabolism  
316 disorders. The interplays among lipid, iron, and copper metabolism have been recognized, but  
317 they are complicated and far away from being fully elucidated. Copper deficiency have long  
318 been linked to increased risks of hyperlipidemia and cardiovascular diseases in both humans and  
319 animal models <sup>32</sup>, while copper supplementation in patients of hyperlipidemia was shown to  
320 improve the blood lipid profile <sup>33</sup>. Epidemiological findings, however, are conflicting, with some  
321 suggesting negative associations of serum copper with both TC and LDL <sup>34</sup>, and others showing  
322 positive associations <sup>35</sup>. The relationship between iron status and blood lipids is similarly  
323 convoluted. On the one hand, some epidemiological studies found that serum iron is lower in  
324 hyperlipidemic patients <sup>36</sup>, and that serum ferritin is negatively associated with LDL <sup>11</sup>. Very  
325 likely related, elevated iron status is negatively associated with coronary artery disease in both  
326 observational and MR studies <sup>37, 38</sup>. Moreover, studies on rats showed that iron deficiency

327 upregulates lipogenic genes but downregulates apolipoprotein H and genes involved in the  
328 mitochondrial beta-oxidation, resulting in increased circulating lipids <sup>39</sup>. On the other hand,  
329 anemic and/or iron-deficient patients and animal models tend to have lower blood TC and LDL  
330 <sup>40</sup>, while serum ferritin has often been found to be positively associated with an unhealthy lipid  
331 profile (i.e., elevated TC, LDL, and triglyceride, but decreased HDL) <sup>41</sup>. To gain mechanistic  
332 insights into how iron regulates lipid metabolism, we performed bioinformatic search for iron  
333 responsive elements in genes involved in cholesterol metabolism and fatty acid degradation <sup>42</sup>.  
334 Multiple potential iron-responsive genes were identified, including LIPH and LDLRAP1 (S1-S2  
335 Figs). Our study highlights iron and copper as risk factors of dyslipidemia and calls for future  
336 studies into their physiological mechanism.

337 Well-known mineral-outcome relationships with established physiological mechanisms  
338 provide support for the power and validity of our study. Iron is an integral component of the  
339 oxygen-carrying hemoglobin and is required for the process of erythropoiesis <sup>4</sup>. In keeping with  
340 this, we found that genetically predicted higher level of serum iron is protective against anemia,  
341 while in women it increases the risks of myeloproliferative disease, polycythemia vera, and  
342 secondary polycythemia. Myeloproliferative diseases are bone marrow and blood disorders  
343 featured by abnormal hematopoiesis, while its most common subtype, polycythemia vera is  
344 characterized by erythrocytosis (i.e., excessive red blood cell production) <sup>43</sup>. Very interestingly,  
345 iron deficiency without anemia is present in virtually all patients of polycythemia vera <sup>44</sup>. Our  
346 findings suggest that iron deficiency is the result, rather than the cause, of erythrocytosis and  
347 reaffirm the current practice of not using iron supplement to treat patients of polycythemia vera.  
348 At the other extreme of systemic status, iron overload can cause tissue damage and its excessive  
349 accumulation in liver leads to cirrhosis and hepatocellular carcinoma <sup>3</sup>. Consistently, our study

350 revealed that elevated serum iron in men is positively associated with risks of chronic liver  
351 disease and cirrhosis, and one of its subtypes, other chronic nonalcoholic liver disease. For  
352 copper, its shared protective effect with iron on iron deficiency anemia also has relatively well-  
353 established mechanistic basis. First, the efflux of iron from enterocyte, hepatocyte, and  
354 macrophage into the blood circulation requires the action of two copper-dependent ferroxidases  
355 (i.e., hephaestin and ceruloplasmin), which oxidize ferrous iron into ferric iron so that it could be  
356 loaded onto transferrin. Besides enabling iron transport, copper is also required for hemoglobin  
357 biosynthesis, probably by assisting iron import into or utilization in mitochondria <sup>45</sup>.

358 Our study revealed the novel causal roles of elevated blood iron in increased risk of varicose  
359 vein. Varicose vein, a common venous disease of the lower extremity, is characterized by  
360 incompetent valves, reflux, and venous wall dilation. Its etiological process involves the  
361 hydrostatic-pressure-induced activation of matrix degrading enzymes and inflammatory cascade  
362 <sup>46</sup>. Iron overload and its causal HFE genetic variations have been associated with varicose vein <sup>47</sup>.  
363 Mechanistically, iron overload induces oxidative stress and hyperactivation of matrix degrading  
364 enzymes <sup>48</sup>. Other significant mineral-outcome relationships are also worth attention. For iron,  
365 our finding of its status increases the risk of glossitis (i.e., tongue inflammation) has been  
366 reported in a previous MR study <sup>49</sup>. However, it is fairly well established that patients of atrophic  
367 glossitis frequently suffer from deficiencies of nutrients, including iron, and corresponding  
368 nutrient supplementation is able to resolve oral symptoms <sup>50</sup>. How to reconcile these findings  
369 should be a subject of future studies. Our findings open many new venues of research to  
370 elucidate the roles of blood iron and copper in these clinical conditions.

371 Our study has strengths and limitations. This is the first comparative PheWAS-MR of iron  
372 and copper, based on a large prospective cohort, to simultaneously evaluate their shared and

373 unique causal clinical effects. Our approach is unbiased and hypothesis-free. The MR approach  
374 reduces the bias from confounding and reverse causality. We utilized strong genetic instruments  
375 and applied multiple sensitivity analyses to detect the presence of pleiotropy. Only MR estimates  
376 with no indications of pleiotropy were reported. For selected outcomes (i.e., blood lipids), we  
377 replicated the results with an independent dataset. The sex-stratified analysis enabled the  
378 identification of sex-specific relationships. Our results confirmed some previous MR findings  
379 while made novel discoveries, most of which are supported by existing epidemiological and  
380 mechanistic studies. Our study also has multiple limitations. Despite a large sample size (N =  
381 310,999) of the overall cohort, the case numbers of specific outcomes are still small, limiting our  
382 statistical power for rare diseases and those with modest effects. Moreover, since our genetic  
383 instruments only proxy blood mineral levels in the normal ranges, some clinical effects of  
384 extreme levels, such as deficiency and overload, are likely missed. Another related issue is that  
385 MR estimation assumes a linear relationship between the exposure and the outcome, and as a  
386 result, non-linear effects might have been missed. Given the well-known threshold effects of  
387 mineral deficiency and overload, future studies with a non-linear model will likely reveal more  
388 clinical effects. Genetic instruments approximate the average effects over the life course, while  
389 the physiological relevance of a blood mineral could vary by life stages and is not captured by  
390 our study. Finally, UK Biobank is a middle- and old-aged cohort and we restricted analysis to  
391 those of European descent, future studies in cohorts of younger ages or other ethnic backgrounds  
392 are needed to confirm our findings and to search for more clinical consequences.

393

394 **Conclusions**

395 In conclusion, our comparative PheWAS-MR study of iron and copper comprehensively  
396 characterized their shared and unique clinical effects. These known and novel mineral-outcome  
397 relationships provide profound insights into the health impacts of normally varying blood  
398 minerals and into the etiologies of some clinical conditions, specifically hyperlipidemia and  
399 hypercholesterolemia. Our findings also emphasize the possibility and importance of managing  
400 blood minerals, probably through dietary adjustment, in the prevention and management of these  
401 medical conditions.

402

403

404 **Acknowledgments**

405 This study was conducted using the UK Biobank Resource under project 48818. The authors  
406 would like to thank all UK Biobank participants. We also want to thank other members of the Ye  
407 lab for stimulating discussions.

408

409 **Funding:** AG is supported by United States Department of Agriculture, National Institute of  
410 Food and Agriculture Hatch Funds. MSR is supported by the Allen Foundation Inc., and the  
411 United States Department of Agriculture (MIN-18-118). KY is supported by the University of  
412 Georgia Research Foundation. The funders had no role in study design, data collection and  
413 analysis, decision to publish, or preparation of the manuscript.

414

415 **Conflict of interest**

416 The authors have declared that no competing interests exist.

417

418 **Data availability statement:** Genetic and phenotypic data from UK Biobank could be accessed  
419 following an application and approval process. Summary statistics generated in this project are  
420 provided in the supplementary files.

421

422 **Abbreviations:** CAD, coronary artery disease; FDR, false discovery rate; GLGC, Global Lipids  
423 Genetics Consortium; ICD, International Classification of Diseases; IVW, inverse variance-  
424 weighted; GRS, polygenic risk score; GWAS, genome-wide association study; HDL, high-  
425 density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; MR, mendelian  
426 randomization; OR, odds ratio; Osteoarthritis: OA; PheWAS, phenome-wide association study;

427 SNP, single nucleotide polymorphism; SD, standard deviation; T2D, type 2 diabetes; TC, total  
428 cholesterol; WM, weighted median;

429

430 **Author Contributions**

431 Conceptualization: Jingqi Zhou, Kaixiong Ye.

432 Data Curation: Jingqi Zhou, Chang Liu, Michael Francis.

433 Formal Analysis: Jingqi Zhou, Chang Liu.

434 Funding Acquisition: Moon-Suhn Ryu, Arthur Grider, Kaixiong Ye.

435 Investigation: Jingqi Zhou, Chang Liu, Arthur Grider, Kaixiong Ye.

436 Methodology: Jingqi Zhou, Kaixiong Ye.

437 Project Administration: Jingqi Zhou, Kaixiong Ye.

438 Resources: Moon-Suhn Ryu, Arthur Grider, Kaixiong Ye.

439 Software: Jingqi Zhou, Chang Liu, Michael Francis, Yitang Sun.

440 Supervision: Kaixiong Ye.

441 Validation: Michael Francis, Yitang Sun, Kaixiong Ye.

442 Visualization: Jingqi Zhou, Chang Liu.

443 Writing – Original Draft Preparation: Jingqi Zhou, Chang Liu.

444 Writing – Review & Editing: Jingqi Zhou, Chang Liu, Michael Francis, Yitang Sun, Moon-Suhn

445 Ryu, Arthur Grider, Kaixiong Ye.

446

447

448 **Reference**

449

450 1. Hunsaker EW and Franz KJ. Emerging Opportunities To Manipulate Metal Trafficking  
451 for Therapeutic Benefit. 2019:13528-13545.

452 2. Waldron KJ, Rutherford JC, Ford D and Robinson NJ. Metalloproteins and metal sensing.  
453 *Nature*. 2009;460:823-830.

454 3. Ferreira CR and Gahl WA. Disorders of metal metabolism. *Transl Sci Rare Dis*.  
455 2017;2:101-139.

456 4. Camaschella C, Pagani A, Nai A and Silvestri L. The mutual control of iron and  
457 erythropoiesis. *Int J Lab Hematol*. 2016;38 Suppl 1:20-6.

458 5. Pietrangelo A. Mechanisms of iron hepatotoxicity. *J Hepatol*. 2016;65:226-227.

459 6. Bandmann O, Weiss KH and Kaler SG. Wilson's disease and other neurological copper  
460 disorders. *Lancet Neurol*. 2015;14:103-13.

461 7. Soma S, Latimer AJ, Chun H, Vicary AC, Timbalia SA, Boulet A, et al. Elesclomol  
462 restores mitochondrial function in genetic models of copper deficiency. *Proc Natl Acad Sci U S*  
463 *A*. 2018;115:8161-8166.

464 8. Bao W, Rong Y, Rong S and Liu L. Dietary iron intake, body iron stores, and the risk of  
465 type 2 diabetes: a systematic review and meta-analysis. *BMC Med*. 2012;10:119.

466 9. Kennish L, Attur M, Oh C, Krasnokutsky S, Samuels J, Greenberg JD, et al. Age-  
467 dependent ferritin elevations and HFE C282Y mutation as risk factors for symptomatic knee  
468 osteoarthritis in males: a longitudinal cohort study. *BMC Musculoskelet Disord*. 2014;15:8.

469 10. Lima SC, Arrais RF, Sales CH, Almeida MG, de Sena KC, Oliveira VT, et al.  
470 Assessment of copper and lipid profile in obese children and adolescents. *Biol Trace Elem Res*.  
471 2006;114:19-29.

472 11. Yu L, Yan J, Zhang Q, Lin H, Zhu L, Liu Q, et al. Association between Serum Ferritin  
473 and Blood Lipids: Influence of Diabetes and hs-CRP Levels. *J Diabetes Res*.  
474 2020;2020:4138696.

475 12. Li J, Bao W, Zhang T, Zhou Y, Yang H, Jia H, et al. Independent relationship between  
476 serum ferritin levels and dyslipidemia in Chinese adults: A population study. *PLoS One*.  
477 2017;12:e0190310.

- 478 13. Davies NM, Holmes MV and Davey Smith G. Reading Mendelian randomisation studies:  
479 a guide, glossary, and checklist for clinicians. *BMJ*. 2018;362:k601.
- 480 14. Davey Smith G and Hemani G. Mendelian randomization: genetic anchors for causal  
481 inference in epidemiological studies. *Hum Mol Genet*. 2014;23:R89-98.
- 482 15. Pichler I, Del Greco MF, Gogele M, Lill CM, Bertram L, Do CB, et al. Serum iron levels  
483 and the risk of Parkinson disease: a Mendelian randomization study. *PLoS Med*.  
484 2013;10:e1001462.
- 485 16. Yuan S and Larsson S. Causal associations of iron status with gout and rheumatoid  
486 arthritis, but not with inflammatory bowel disease. *Clin Nutr*. 2020.
- 487 17. Kodali HP, Pavilonis BT and Schooling CM. Effects of copper and zinc on ischemic  
488 heart disease and myocardial infarction: a Mendelian randomization study. *Am J Clin Nutr*.  
489 2018;108:237-242.
- 490 18. Cheng WW, Zhu Q and Zhang HY. Mineral Nutrition and the Risk of Chronic Diseases:  
491 A Mendelian Randomization Study. *Nutrients*. 2019;11.
- 492 19. Benyamin B, Esko T, Ried JS, Radhakrishnan A, Vermeulen SH, Traglia M, et al. Novel  
493 loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis. *Nat*  
494 *Commun*. 2014;5:4926.
- 495 20. Gill D, Monori G, Tzoulaki I and Dehghan A. Iron Status and Risk of Stroke. *Stroke*.  
496 2018;49:2815-2821.
- 497 21. Evans DM, Zhu G, Dy V, Heath AC, Madden PA, Kemp JP, et al. Genome-wide  
498 association study identifies loci affecting blood copper, selenium and zinc. *Hum Mol Genet*.  
499 2013;22:3998-4006.
- 500 22. Wu P, Gifford A, Meng X, Li X, Campbell H, Varley T, et al. Mapping ICD-10 and ICD-  
501 10-CM Codes to Phecodes: Workflow Development and Initial Evaluation. *JMIR Med Inform*.  
502 2019;7:e14325.
- 503 23. Burgess S, Butterworth A and Thompson SG. Mendelian randomization analysis with  
504 multiple genetic variants using summarized data. *Genet Epidemiol*. 2013;37:658-65.
- 505 24. Bowden J, Davey Smith G, Haycock PC and Burgess S. Consistent Estimation in  
506 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator.  
507 *Genet Epidemiol*. 2016;40:304-14.

- 508 25. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base  
509 platform supports systematic causal inference across the human phenome. *Elife*. 2018;7.
- 510 26. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al.  
511 Discovery and refinement of loci associated with lipid levels. *Nature Genetics*. 2013;45:1274-  
512 1283.
- 513 27. Sanderson E, Davey Smith G, Windmeijer F and Bowden J. An examination of  
514 multivariable Mendelian randomization in the single-sample and two-sample summary data  
515 settings. *Int J Epidemiol*. 2019;48:713-727.
- 516 28. Burgess S and Thompson SG. Interpreting findings from Mendelian randomization using  
517 the MR-Egger method. *Eur J Epidemiol*. 2017;32:377-389.
- 518 29. Kamat MA, Blackshaw JA, Young R, Surendran P, Burgess S, Danesh J, et al.  
519 PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations.  
520 *Bioinformatics*. 2019;35:4851-4853.
- 521 30. Yavorska OO and Burgess S. MendelianRandomization: an R package for performing  
522 Mendelian randomization analyses using summarized data. *Int J Epidemiol*. 2017;46:1734-1739.
- 523 31. Verbanck M, Chen CY, Neale B and Do R. Detection of widespread horizontal  
524 pleiotropy in causal relationships inferred from Mendelian randomization between complex traits  
525 and diseases. *Nat Genet*. 2018;50:693-698.
- 526 32. DiNicolantonio JJ, Mangan D and O'Keefe JH. Copper deficiency may be a leading cause  
527 of ischaemic heart disease. *Open Heart*. 2018;5:e000784.
- 528 33. Alarcon-Corredor OM, Guerrero Y, Ramirez de Fernandez M, D'Jesus I, Burguera M,  
529 Burguera JL, et al. Effect of copper supplementation on lipid profile of Venezuelan hyperlipemic  
530 patients. *Arch Latinoam Nutr*. 2004;54:413-8.
- 531 34. Bo S, Durazzo M, Gambino R, Berutti C, Milanesio N, Caropreso A, et al. Associations  
532 of dietary and serum copper with inflammation, oxidative stress, and metabolic variables in  
533 adults. *J Nutr*. 2008;138:305-10.
- 534 35. Zang X, Huang H, Zhuang Z, Chen R, Xie Z, Xu C, et al. The association between serum  
535 copper concentrations and cardiovascular disease risk factors in children and adolescents in  
536 NHANES. *Environ Sci Pollut Res Int*. 2018;25:16951-16958.
- 537 36. Zhu Y, He B, Xiao Y and Chen Y. Iron metabolism and its association with dyslipidemia  
538 risk in children and adolescents: a cross-sectional study. *Lipids Health Dis*. 2019;18:50.

- 539 37. Das De S, Krishna S and Jethwa A. Iron status and its association with coronary heart  
540 disease: systematic review and meta-analysis of prospective studies. *Atherosclerosis*.  
541 2015;238:296-303.
- 542 38. Gill D, Brewer CF, Monori G, Tregouet DA, Franceschini N, Giambartolomei C, et al.  
543 Effects of Genetically Determined Iron Status on Risk of Venous Thromboembolism and Carotid  
544 Atherosclerotic Disease: A Mendelian Randomization Study. *J Am Heart Assoc*. 2019;8:e012994.
- 545 39. Davis MR, Rendina E, Peterson SK, Lucas EA, Smith BJ and Clarke SL. Enhanced  
546 expression of lipogenic genes may contribute to hyperglycemia and alterations in plasma lipids  
547 in response to dietary iron deficiency. *Genes Nutr*. 2012;7:415-25.
- 548 40. Özdemir A, Sevinç C, Selamet U and Türkmen F. The Relationship Between Iron  
549 Deficiency Anemia and Lipid Metabolism in Premenopausal Women. *The American Journal of*  
550 *the Medical Sciences*. 2007;334:331-333.
- 551 41. Wrede CE, Buettner R, Bollheimer LC, Scholmerich J, Palitzsch KD and Hellerbrand C.  
552 Association between serum ferritin and the insulin resistance syndrome in a representative  
553 population. *Eur J Endocrinol*. 2006;154:333-40.
- 554 42. Campillos M, Cases I, Hentze MW and Sanchez M. SIREs: searching for iron-responsive  
555 elements. *Nucleic Acids Res*. 2010;38:W360-7.
- 556 43. Spivak JL. Myeloproliferative Neoplasms. *N Engl J Med*. 2017;377:895-6.
- 557 44. Ginzburg YZ, Feola M, Zimran E, Varkonyi J, Ganz T and Hoffman R. Dysregulated  
558 iron metabolism in polycythemia vera: etiology and consequences. *Leukemia*. 2018;32:2105-  
559 2116.
- 560 45. Doguer C, Ha JH and Collins JF. Intersection of Iron and Copper Metabolism in the  
561 Mammalian Intestine and Liver. *Compr Physiol*. 2018;8:1433-1461.
- 562 46. Kucukguven A and Khalil RA. Matrix metalloproteinases as potential targets in the  
563 venous dilation associated with varicose veins. *Curr Drug Targets*. 2013;14:287-324.
- 564 47. Fukaya E, Flores AM, Lindholm D, Gustafsson S, Zanetti D, Ingelsson E, et al. Clinical  
565 and Genetic Determinants of Varicose Veins. *Circulation*. 2018;138:2869-2880.
- 566 48. Zamboni P, Scapoli G, Lanzara V, Izzo M, Fortini P, Legnaro R, et al. Serum iron and  
567 matrix metalloproteinase-9 variations in limbs affected by chronic venous disease and venous leg  
568 ulcers. *Dermatol Surg*. 2005;31:644-9; discussion 649.

- 569 49. Gill D, Benyamin B, Moore LSP, Monori G, Zhou A, Koskeridis F, et al. Associations of  
570 genetically determined iron status across the phenome: A mendelian randomization study. *PLoS*  
571 *Med.* 2019;16:e1002833.
- 572 50. Chiang CP, Chang JY, Wang YP, Wu YH, Wu YC and Sun A. Atrophic glossitis:  
573 Etiology, serum autoantibodies, anemia, hematinic deficiencies, hyperhomocysteinemia, and  
574 management. *J Formos Med Assoc.* 2020;119:774-780.  
575




Fig 1: A flow chart of the study design.




Fig 2. A forest plot showing significant mineral-outcome associations based on MR analysis. The causal estimates are from IVW MR and have no indications of pleiotropy. The odds ratios (ORs) with their 95% confidence intervals (CIs) are scaled to 1-SD increase in blood iron or copper level. Complete MR results are provided in S4 Tables.




Fig 3. A forest plot showing significant mineral-outcome associations based on sex-stratified MR analysis. Results in male, female, and the combined analyses are shown. The causal estimates are from IVW MR and have no indications of pleiotropy. The odds ratios (ORs) with their 95% confidence intervals (CIs) are scaled to 1-SD increase in blood mineral level. Complete MR results are provided in S6 Tables.

Tables

Table 1: SNPs used as genetic instruments for blood minerals in the PheWAS and MR analyses.

SNP	Effect allele	Baseline allele	Chr	Closest gene	% variance explained	F-statistic	EAF	Beta <sup>a</sup>	SE	P
3 SNPs for Fe from Benyamin et al. (N <sup>b</sup> = 48,972)										
rs1800562	A	G	6	HFE	1.30	645	0.067	0.328	0.016	2.72×10 <sup>-97</sup>
rs1799945	G	C	6	HFE	0.90	445	0.15	0.189	0.010	1.10×10 <sup>-81</sup>
rs855791	G	A	22	TMPRSS6	1.60	796	0.554	0.181	0.007	1.32×10 <sup>-139</sup>
2 SNPs for Cu from Evans et al. (N <sup>b</sup> = 2,603)										
rs1175550	G	A	1	SMIM1	1.45	38	0.23	0.198	0.032	5.03×10 <sup>-10</sup>
rs2769264	G	T	1	SELENBP1	3.15	85	0.18	0.313	0.034	2.63×10 <sup>-20</sup>

SNP single nucleotide polymorphism, Chr: chromosome, EAF: effect allele frequency, SE: standard error,

a. The beta coefficient of mineral increasing allele on concentrations of serum iron (in μmol/L), erythrocyte copper (in mmol/L).

b. The sample size of the GWAS or meta-analysis from which the genetic variants were selected.

Table 2: MR analyses of iron and copper on blood lipids in UK Biobank and GLGC

Exposure/Outcome	MR method	beta	SE	OR (95% CI)	Peffect	Ppleiotropy	n_total	Data
<b>Iron</b>								
HDL cholesterol	WM	-0.008	0.015	0.99 (0.96-1.02)	0.602	-		
	IVW	-0.003	0.013	1.00 (0.97-1.02)	0.801	0.396	183,990	GLGC
	MR Egger	-0.062	0.055	0.94 (0.84-1.05)	0.459	0.430		
HDL cholesterol	WM	-0.005	0.004	1.00 (0.99-1.01)	0.231	-		
	IVW	-0.002	0.004	1.00 (0.99-1.00)	0.589	0.162	224,140	UKBB
	MR Egger	-0.021	0.014	0.98 (0.95-1.01)	0.361	0.385		
LDL cholesterol	WM	-0.058	0.019	0.94 (0.91-0.98)	0.002	-		
	IVW	-0.100	0.043	0.91 (0.83-0.98)	0.020	6×10 <sup>-5</sup>	169,960	GLGC
	MR Egger	-0.351	0.059	0.70 (0.63-0.79)	0.106	0.143		
LDL cholesterol	WM	-0.089	0.014	0.91 (0.89-0.94)	5.27×10 <sup>-11</sup>	-		
	IVW	-0.083	0.042	0.92 (0.85-0.99)	0.048	7.6×10 <sup>-13</sup>	244,476	UKBB
	MR Egger	-0.279	0.127	0.76 (0.59-0.97)	0.271	0.356		
Total cholesterol	WM	-0.047	0.019	0.95 (0.92-0.99)	0.013	-		
	IVW	-0.083	0.044	0.92 (0.84-1.00)	0.060	1.9×10 <sup>-5</sup>	184,158	GLGC
	MR Egger	-0.342	0.057	0.71 (0.64-0.79)	0.106	0.135		
Total cholesterol	WM	-0.096	0.018	0.91 (0.88-0.94)	8.99×10 <sup>-8</sup>	-		
	IVW	-0.090	0.056	0.91 (0.82-1.02)	0.109	9.8×10 <sup>-14</sup>	244,950	UKBB
	MR Egger	-0.359	0.162	0.70 (0.51-0.96)	0.270	0.336		
Triglycerides	IVW	0.034	0.012	1.04 (1.01-1.06)	0.006	0.958		
	WM	0.033	0.013	1.03 (1.01-1.06)	0.014	-	174,687	GLGC
	MR Egger	0.049	0.053	1.05 (0.95-1.17)	0.524	0.986		
Triglycerides	WM	0.047	0.012	1.05 (1.02-1.07)	4.2×10 <sup>-5</sup>	-		
	IVW	0.043	0.016	1.04 (1.01-1.08)	0.006	0.043	244,754	UKBB
	MR Egger	-0.040	0.035	1.03 (1.01-1.16)	0.463	0.250		
<b>Copper</b>								
HDL cholesterol	IVW	0.004	0.028	1.00 (0.95-1.06)	0.880	0.116	94,311	GLGC
	IVW	0.002	0.003	1.00 (1.00-1.01)	0.448	0.885	221,738	UKBB
LDL cholesterol	IVW	-0.048	0.019	0.95 (0.92-0.99)	0.011	0.785	89,888	GLGC
	IVW	-0.008	0.013	0.99 (0.97-1.02)	0.543	0.100	241,831	UKBB
Total cholesterol	IVW	-0.043	0.018	0.96 (0.92-0.99)	0.020	0.823	94,595	GLGC
	IVW	-0.013	0.016	0.99 (0.96-1.02)	0.388	0.121	242,304	UKBB
Triglycerides	IVW	-0.024	0.020	0.98 (0.94-1.02)	0.233	0.241	91,013	GLGC
	IVW	-0.008	0.009	0.99 (0.87-1.01)	0.333	0.874	242,112	UKBB

## Supporting Information

S1 Checklist: STROBE checklist. STROBE, Strengthening the Reporting of Observational Studies in Epidemiology.

S1 Fig: Genes in the KEGG pathway of cholesterol metabolism predicted to carry iron response elements. Predictions with high, medium, and low confidence are shown in yellow, blue, and orange, respectively.

S2 Fig: Genes in the KEGG pathway of fatty acid degradation predicted to carry iron response elements. Predictions with high, medium, and low confidence are shown in yellow, blue, and orange, respectively.

S1 Table: The number of phenotypes and cases considered in each disease category.

S2 Table: Descriptive characteristics of the UK Biobank participants and the SNPs included in PheWAS analyses.

S3 Table: The association between the weighted GRS of each blood mineral and common confounding factors.

S4 Table: Lists of significant mineral-outcome relationships without indications of pleiotropy.

S5 Table: Multivariate IVW MR results for iron and copper.

S6 Table: Lists of significant mineral-outcome relationships without indications of pleiotropy based on sex-stratified MR analysis.